IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Xunfei Healthcare 02506.HK	Application Software	82.8	50	N/A	2024/12/23	Data is not available	2024/12/30
InnoScience 02577.HK	Semiconductors & Semiconductor Equipment	30.86-33.66	100	3,400	2024/12/23	Data is not available	2024/12/30
HealthyWay 02587.HK	Health Care Services	7.8-8.8	500	4,444	2024/12/23	Data is not available	2024/12/30

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Xunfei Healthcare
02506.HK

Application Software

82.8

N/A

2024/12/23

Data is not available

2024/12/30

InnoScience
02577.HK

Semiconductors & Semiconductor Equipment

30.86-33.66

100

3,400

2024/12/23

Data is not available

2024/12/30

HealthyWay
02587.HK

Health Care Services

7.8-8.8

500

4,444

2024/12/23

Data is not available

2024/12/30

Summary

Our mission is to advance the innovation and accelerate the adoption of cancer screening technologies in China. Founded in November 2015, we are the pioneer in China's colorectal cancer screening market with ColoClear, our proprietary, non-invasive, multi-target, FIT-DNA test, being the first and only molecular cancer screening test in China approved by NMPA, according to Frost & Sullivan. ColoClear targets a 120 million high-risk colorectal cancer population in China, and enables users to collect stool sample at home and avoid invasive procedures while delivering high testing sensitivity and specificity. In our registrational trial with 5,881 enrolled subjects, ColoClear has demonstrated clinical results of a sensitivity of 95.5% for colorectal cancer and 63.5% for advanced adenoma, an overall specificity of 87.1%, NPV of 99.6% for colorectal cancer, and PPV of 46.2% for colorectal cancer and advanced adenoma collectively. We believe that our proprietary technologies, clinical performance, regulatory and operational expertise, and solid relationships with KOLs serve as high entry barriers and differentiate us from our peers. We may not be able to fully capture the target populations of our products. As of the Latest Practicable Date, we had not commercialized ColoClear IVD. Whether ColoClear can fully capture the 120 million high-risk colorectal cancer population in China depends on various factors, such as the commercialization of ColoClear IVD as a standalone medical device, inclusion of ColoClear under national public medical insurance program and continuous policy support from the PRC government. See “Risk Factors – Risks Relating to Commercialization and Distribution of our Products – The sizes of the markets for our current and future products have not been established with precision, and may be smaller than we estimate, and we may not be able to fully capture the target populations of our products.” We operate in a largely untapped and fast-growing colorectal cancer screening market in China. Colorectal cancer is one of the most deadly cancer types in China, both by incidence and mortality rates. However, it is not only curable if diagnosed at early cancer stage, but also preventable if discovered at precancerous stage. In line with the PRC government's initiatives to promote cancer screening and lower expenditures on China's healthcare system, the colorectal cancer screening market in China is expected to grow significantly with the availability of more effective screening solutions and increased awareness of cancer screening. According to Frost & Sullivan, the colorectal cancer screening market in China has grown from RMB2.5 billion in 2015 to RMB3.0 billion in 2019, and is expected to further grow to RMB19.8 billion in 2030, representing a CAGR of 18.7% from 2019 to 2030. On the other hand, the colorectal cancer screening market in China remains largely untapped with a penetration rate of 16.4% in 2019, compared with 60.1% in the U.S., according to Frost & Sullivan. To capitalize on this market opportunity and to address the unmet cancer screening demands in China, we were founded in 2015 by our experienced founders to focus on the design, development and commercialization of cancer screening tests. Our Chief Executive Officer, Mr. Yeqing Zhu, has more than 20 years of management experience in Fortune 500 multinational companies and currently serves as a council member of the Cancer Foundation of China. Our Chief Scientific Officer, Dr. Yiyou Chen, has more than 20 years of research and development experience in the oncology space, is the inventor of six patents in the U.S. and over 20 patent applications globally, and has authored multiple papers published in peerreviewed medical journals. Our Chief Technology Officer, Dr. Ning Lu, has over a decade of IVD development experience at multiple global companies, including Roche Diagnostics and Quest Diagnostics, and led the development of eight IVD products. Under their leadership, we have strategically developed a robust pipeline for cancer screening tests with a focus on vast market demand, clinical utility and technology compatibility. Our two home-based colorectal cancer screening tests, ColoClear and Pupu Tube, synergistically address target populations with various risk levels. Pupu Tube, our proprietary, non-invasive, stool-based FIT test, is the first and only self-conducted FIT screening product approved by NMPA in China. Pupu Tube targets mass market in China with a 633 million population in 2019 recommended for colorectal cancer screening to increase colorectal cancer screening awareness and identify high-risk population. In addition, we have two late-stage product candidates for gastric and cervical cancer screening respectively. We are developing our UU Tube, a stool-based self-conducted screening test for gastric cancer. We completed the registrational trial of UU Tube in November 2020 and submitted registration application to NMPA in the same month of 2020. We are also developing our CerviClear, a non-invasive urine-based home-use screening test for cervical cancer. We expect to initiate the registrational trial for CerviClear by as early as the last quarter of 2021. Source: New Horizon Health-B (06606) Prospectus (IPO Date : 05/02/2021)
Listing Market	MAIN
Industry	Biotechnology
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Naxin YAO & Associates (8.27%) Yiyou CHEN & Family (7.98%) Qiming Corporate GP V, Ltd. (7.84%) Invesco Advisors, Inc. (7.01%) Yeqing ZHU (6.15%)
Directors	Yeqing ZHU (Co-Founder and Chairman and Chief Executive Officer and Executive Director) Yiyou CHEN (Co-Founder and Executive Director) Naxin YAO (Non-Executive Director) Danke YU (Independent Non-Executive Director) Kwok Tung LI, Donald (Independent Non-Executive Director) Lau Ngai Kee Ricky (Independent Non-Executive Director) Ng Weng Sin (Independent Non-Executive Director) Jiangnan Kong (Independent Non-Executive Director)
Company Secretary	Leung Wing Han Sharon
Principal Bankers	China Merchants Bank Silicon Valley Bank
Solicitors
Auditors
Registered Office	5th Floor, Manulife Place 348 Kwun Tong Road, Kowloon, Hong Kong
Share Registrars	Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No	(852) 2980-1333
Internet Address	https://ir.newhorizonbio.com
Email Address	IR@nhbio.com.cn
Tel No	(86 571) 8110-7210
Fax No	(86 571) 8643-0935

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates